BackExcelsior Biopharma Overview

Excelsior Biopharma Total Liabilities

Track Excelsior Biopharma's total liabilities ($730M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$728.80M
↑ 40.02% YoYΔ $208.32M vs prior year quarter

Peer trimmed avg / median

Loading

Excelsior Biopharma Total Liabilities History

Loading

Excelsior Biopharma vs. peers: Total Liabilities Comparison

Loading

Excelsior Biopharma Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Excelsior Biopharma (6496.TWO) FAQ

Excelsior Biopharma posts a total liabilities of $730M as of June 2026. That compares with $520M in the prior-year period — up 40.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Excelsior Biopharma's total liabilities was $520M. The latest reading is $730M — a 40.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Excelsior Biopharma's financial statement story. At $730M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 6496.TWO's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Excelsior Biopharma's other metric pages and overview cover the third.